UK drugmaker GlaxoSmithKline (LSE: GSK) has impressed investors with its first quarter 2022 financial results, with its share price closing 3% higher on Wednesday.
GSK is in an important year, with plans to split off its Consumer Healthcare unit in July, and many eyes on the progress of its Biopharma business as it prepares to go it alone.
This article is accessible to registered users, to continue reading please register for free. A free trial will give you access to exclusive features, interviews, round-ups and commentary from the sharpest minds in the pharmaceutical and biotechnology space for a week. If you are already a registered user please login. If your trial has come to an end, you can subscribe here.
Login to your accountTry before you buy
7 day trial access
Become a subscriber
Or £77 per month
The Pharma Letter is an extremely useful and valuable Life Sciences service that brings together a daily update on performance people and products. It’s part of the key information for keeping me informed
Chairman, Sanofi Aventis UK
Copyright © The Pharma Letter 2024 | Headless Content Management with Blaze